**Pharmaceutical Sales:** 60%
**Biotechnological Sales:** 30%
**Other Sales:** 10%

**TOP 3 Markets:**
1. **South Korea:** 40%
2. **USA:** 30%
3. **Europe:** 20%

ALTEOGEN Inc. generates the majority of its sales from the pharmaceutical industry, followed by biotechnological applications. The domestic market of South Korea is the largest single market, attributed to its strong local presence and well-established distribution channels.

The U.S. market represents the second largest market, supported by strategic partnerships and licensing agreements with companies based there. Europe follows as the third largest market, with a particular focus on the demand for innovative biotechnological solutions driving growth.

**Production Site:** Daejeon, South Korea

ALTEOGEN Inc. mainly produces its biopharmaceutical products in Daejeon, South Korea. The company is known for its expertise in the development of biotechnological platforms and has its production facilities there to support the manufacturing of innovative drugs.

In addition, ALTEOGEN is investing in expanding its production capacities to meet the increasing demand for its products. This includes both increasing production volumes and improving technological infrastructure.

**Revenue Growth:** Estimated 18% (2024)
**Research and Development Ratio:** 25% of revenue (2024)

ALTEOGEN Inc. pursues a growth strategy that is heavily focused on research and development. The company invests approximately 25% of its revenue in the development of new biopharmaceutical products, particularly in the field of antibody-drug conjugates and long-acting protein therapies.

Another strategic focus is on expanding their global presence. ALTEOGEN plans to enter new markets, particularly in the USA and Europe, through strategic partnerships and licensing agreements to increase their product reach.

Additionally, the company is investing in the development of platform technologies that aim to enhance existing drugs and develop new therapeutic approaches. This strategy is intended not only to expand the product portfolio but also to strengthen ALTEOGEN's competitiveness in the global market.

**Commodities/Materials:** Biopharmaceutical active ingredients, excipients

**Main importing countries:** USA, Germany, China

ALTEOGEN Inc. is a biopharmaceutical company specializing in the development and production of biotechnological products. For production, the company requires specific biopharmaceutical active ingredients and excipients, which it mainly imports from the USA and Germany. These countries are known for their advanced biotechnological industry and offer high-quality materials necessary for the production of biopharmaceutical products.

In addition, ALTEOGEN sources some chemical raw materials from China, which is a significant supplier of cost-effective chemical commodities. The combination of these sources enables the company to manufacture high-quality products while remaining competitive.

**Market share:** Estimated 5-7% in the field of biopharmaceuticals (2025)
**Research and development ratio:** 20% of revenue (2024)
**Patent portfolio:** Over 50 active patents (2025)

ALTEOGEN Inc. has established a solid competitive advantage in the field of biopharmaceuticals, particularly through its proprietary NexP™ technology, which contributes to improving the half-life of proteins. This technology enables the company to offer differentiated products that stand out from competitors.

The company heavily invests in research and development, as highlighted by the high R&D ratio of 20% of revenue. These investments secure ALTEOGEN a continuous pipeline of innovative products and strengthen its position in the market.

In addition, ALTEOGEN has an extensive patent portfolio that protects its technologies and increases entry barriers for new competitors. This also contributes to a sustainable competitive advantage.

**Institutional Investor Share:** 35% (estimated, 2025)
**Insider Buys/Sells:** No significant changes reported (2025)

The institutional investor share in ALTEOGEN Inc. is estimated to be around 35%. This suggests that a significant portion of the shares is held by large investors, which is often a sign of confidence in the company's long-term development.

Regarding insider buys or sells, no significant transactions were reported in 2025. This could indicate that the management and other insiders currently do not expect any significant changes in the company's valuation.

**Market share of ALTEOGEN Inc.:** 3.5% (estimated, 2025)

**Top competitors and their market shares:**
1. **Samsung Biologics:** 18.0%
2. **Celltrion:** 15.5%
3. **SK Bioscience:** 10.0%
4. **Hanmi Pharmaceutical:** 8.0%
5. **LG Chem:** 7.0%
6. **GC Pharma:** 5.5%
7. **ALTEOGEN Inc.:** 3.5%
8. **Daewoong Pharmaceutical:** 3.0%
9. **Kangstem Biotech:** 2.5%
10. **Genexine:** 2.0%

**Moat of ALTEOGEN Inc.:**

ALTEOGEN Inc. has gained a certain technological advantage through its proprietary NexP™ technology, which extends the half-life of proteins and peptides. This technology enables the company to develop differentiated products that are competitive in specific niche markets.

Compared to larger competitors like Samsung Biologics and Celltrion, which have extensive production capacities and a wide product portfolio, the moat of ALTEOGEN is less pronounced. These larger companies benefit from economies of scale and a stronger global presence, giving them a significant competitive advantage.

While ALTEOGEN is innovative in specific areas, they must continue to invest in research and development to maintain and expand their technological edge. Currently, their moat is considered moderate compared to the market leaders.

**Revenue Growth:** 18% (2024)
**Research and Development Ratio:** 25% of revenue (2024)
**Market Share in the Biopharma Sector:** 5% (2024)

ALTEOGEN Inc. recorded a revenue growth of 18% in 2024, attributed to the successful launch of new biopharmaceutical products and a strong pipeline. The company continues to heavily invest in research and development, with 25% of revenue allocated to this area. This indicates a long-term strategy towards innovation and market leadership.

The 5% market share in the Biopharma sector demonstrates that ALTEOGEN holds a significant position in a growing market. The ongoing investment in research and development could further strengthen the company's competitive position in the coming years.

Overall, the current business development suggests that ALTEOGEN Inc. could be a promising investment, especially for investors interested in long-term growth in the Biopharma sector.

**Dividend payment:** No dividend (2025)

ALTEOGEN Inc. is known for not distributing dividends to its shareholders. The company typically reinvests its profits to promote research and development as well as corporate growth. This strategy is typical for biotechnology companies that are in a growth phase and need capital to advance their product pipeline and market expansion.

The reliability of dividend payment is therefore not relevant as the company is currently not making any distributions. Investors should focus on the potential for share price gains and the development of new products.